1. Introduction {#s0005}
===============

For men and women worldwide, liver cancer ranks as the second and sixth leading cause of cancer deaths, respectively ([@bb0295]). In 2012, there were an estimated 782,500 new cases of liver cancer and 745,500 deaths worldwide, and the incidence of the disease is rising ([@bb0295]). Hepatocellular carcinoma (HCC) account for \> 90% of primary liver cancer cases, and epidemiological studies have revealed that chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection, exposure to aflatoxin, alcohol consumption, cigarette smoking, diabetes, and susceptibility genetic factors are major risk factors for HCC ([@bb0060], [@bb0070], [@bb0400]). The prognosis for HCC patients is poor: the 5-year survival rate for localized HCC patients is 30.5%, and this rate drops below 5% for those with distant metastases according to the Surveillance, Epidemiology, and End Results (SEER) database ([@bb0065], [@bb0235]). For patients at early disease stages, liver resection is the most effective treatment methods; however, fewer than 30% of HCC patients are eligible for this treatment, and approximately 70% of them will relapse within 5 years of treatment ([@bb0120]). Thus, it is necessary to identify those prognostic factors and systematically evaluate patient characteristics to guide the postoperative treatments and surveillance, which may improve the prognosis of HCC patients.

Similar to other solid tumors, the characteristics such as tumor size, tumor differentiation, tumor node numbers, vascular invasion, and metastasis status are important prognosis factors for HCC patients ([@bb0225]). These characteristics constitute the tumor-node-metastasis (TNM) classification system for HCC patients ([@bb0285]). In addition to these tumor characteristics, biomarkers for preserved liver function and the liver damage status of the HCC patients, such as the Child-Pugh stage; the α-fetoprotein (AFP), bilirubin, and albumin levels; and ECOG status are also associated with the prognosis of HCC patients. These additionally markers have led to the establishment of various conventional staging systems, including the Japan Integrated Staging (JIS) system ([@bb0155]), the Barcelona Clinic Liver Cancer (BCLC) classification system ([@bb0195]), the Cancer of the Liver Italian Program (CLIP) scoring system ([@bb0215]) and the Chinese University Prognostic Index (CUPI) scoring system ([@bb0180]). These systems are widely used to guide the treatment methods and/or predict the outcomes of HCC patients. However, the clinical performance of these systems depends on the patient characteristics, the treatments performed, and the disease etiology of the patients ([@bb0200], [@bb0290]). Moreover, although these staging and scoring systems can stratify the HCC patients into appropriate risk categories, a great deal of divergence remains within each risk category due to the molecular heterogeneity of tumor cells and the tumor microenvironment ([@bb0080]). An in-depth characterization and understanding of the molecular basis of the tumor and its corresponding microenvironment are critical for improving the diagnosis, identifying prognostic and predictive biomarkers, and developing effective therapeutic strategies ([@bb0150]).

Genome-wide expression profiling methods provide detailed information regarding the diversity of diseases and are valuable for the disease diagnosis, therapeutic response prediction and prognosis evaluation. Currently, many studies have assessed the prognostic effects of array-based gene expression signatures obtained from HCC tumors ([@bb0005], [@bb0020], [@bb0030], [@bb0040], [@bb0045], [@bb0050], [@bb0105], [@bb0115], [@bb0135], [@bb0140], [@bb0145], [@bb0160], [@bb0165], [@bb0185], [@bb0205], [@bb0255], [@bb0260], [@bb0265], [@bb0315], [@bb0340], [@bb0360], [@bb0365], [@bb0390], [@bb0405], [@bb0410]) or from adjacent, non-tumor tissues ([@bb0025], [@bb0110], [@bb0230]). These investigations have identified gene signatures that predict recurrence and/or mortality for HCC patients; however, none has entered clinical use, perhaps due to their low reproducibility and lack of standardized determination methods. Interestingly, overlapping genes between these gene signatures are rare, and this rarity may be related to the disease stage of the patients, the main hypothesis of the study, the platform applied, and/or the data mining methods that were utilized. However, these gene signatures with little overlap might be functionally linked with each other and form a systematic molecular regulation network that is robust for patient stratification. Herein, we systematically evaluated the generalization of the prognostic gene signatures in independent HCC case cohorts and established a functional protein-protein interaction (PPI) network for gene signatures that have reproducible prognostic values. Through the PPI network topological analysis, we identified those critical molecules in the network and determined their values as biomarkers for prognosis assessment or as therapeutic targets for HCC patients.

2. Methods and Materials {#s0010}
========================

2.1. Identification of Candidate HCC Prognostic Gene Signatures {#s0015}
---------------------------------------------------------------

The PubMed database, published up to April 30, 2016, was searched to identify gene signatures that have prognostic effects for HCC patients. The terms ("liver cancer" or "hepatocellular carcinoma") AND ("prognosis" or "overall survival" or "outcome" or "mortality") AND ("gene expression" or "gene signature" or "expression profiling") were used. A total of 1713 original publications were identified in our initial database search. Through checking the titles and abstracts of studies, we excluded those studies that were only performed in the cellular or animal models but not in the human populations. Comments, reviews, abstracts or short communications without sufficient information were also excluded. Thus, 89 publications were selected and further checked in full length to identify gene signatures that might be associated with the overall survival (OS) of HCC patients. Excluded were gene signatures derived from cell lines, specific biological signaling, microRNA expression, long non-coding RNA expression, and methods based on real-time PCR (RT-PCR). Gene signatures derived from tumor microenvironment samples were also excluded because we specifically focused on gene expression information derived from the tumor tissues here. A total of 30 gene signatures from 25 studies were identified, and their prognostic performance in HCC patients was determined \[15-39\] ([Table 1](#t0005){ref-type="table"}).Table 1Gene signatures included in the nearest-template prediction studies of the [GSE14520](ncbi-geo:GSE14520){#ir0075} (N = 242) and [GSE54236](ncbi-geo:GSE54236){#ir0080} (N = 78) datasets.Table 1StudyYearSignature names (Molecular Signature Database \[MSIGBD\][a](#tf0005){ref-type="table-fn"})Signature name in the studyNo. of genes in the signatureGenes covered in [GSE14520](ncbi-geo:GSE14520){#ir0085}Samples with the signature ([GSE14520](ncbi-geo:GSE14520){#ir0090})[b](#tf0010){ref-type="table-fn"}Genes covered in [GSE54236](ncbi-geo:GSE54236){#ir0095}Samples with the signature ([GSE54236](ncbi-geo:GSE54236){#ir0100})[b](#tf0010){ref-type="table-fn"}Iizuka et al.2003IIZUKA_LIVER_CANCER_EARLY_RECURRENCE_DNRecurrence_Lizuka1212 (100.0%)NA12 (100.0%)NAYe et al.2003YE_METASTATIC_LIVER_CANCERMetastasis_Ye2828 (100.0%)NA27 (96.4%)NALee et al.2004LEE_LIVER_CANCER_POOR-SURVIVAL_UP, \_DNLee_OS360316 (87.8%)202 (83.5%)355 (98.6%)69 (88.5%)Korukawa et al.2004Early_recurrence_signature^c^Recurrence_Korukawa1917 (89.5%)NA19 (100.0%)NAKaposi-Novak et al.2006NOVAK_LIVER_CANCER_MET_UP, \_DNMET_Kaposi-Novak2424 (100.0%)66 (27.3%)24 (100%)24 (30.8%)Boyault et al.2007BOYAULT_LIVER_CANCER_SUBCLASS_G3_UP, \_DNG3_Boyault239239 (100.0%)192 (79.3%)239 (100.0%)64 (82.1%)Boyault et al.2007BOYAULT_LIVER_CANCER_SUBCLASS_G56_UP,\_DNG5/6_Boyault2929 (100.0%)78 (32.2%)29 (100.0%)21 (26.9%)Boyault et al.2007BOYAULT_LIVER_CANCER_SUBCLASS_G6_UP,\_DNG6_Boyault8484 (100.0%)69 (28.5%)84 (100.0%)26 (33.3%)Wang et al.2007WANG_RECURRENT_LIVER_CANCER_UP,\_DNRecurrence_Wang3632 (88.9%)75 (31.0%)36 (100.0%)20 (25.6%)Cairo et al.2008C2_POOR-PROGNOSIS_UP, \_DNC2_Cario1616 (100.0%)102 (42.1%)16 (100.0%)29 (37.2%)Chiang et al.2008CHIANG_LIVER_CANCER_SUBCLASS_CTNNB1_UP,\_DNCTNNB1_Chiang346280 (80.9%)134 (55.4%)343 (99.1%)57 (73.1%)Chiang et al.2008CHIANG_LIVER_CANCER_SUBCLASS_INTERFERON_UP,\_DNInterfron_Chiang7857 (73.1%)85 (35.15)77 (98.7%)33 (42.3%)Chiang et al.2008CHIANG_LIVER_CANCER_SUBCLASS_PROLIFERATION_UP,\_DNProliferation_Chiang357299 (83.8%)198 (81.8%)353 (98.9%)68 (87.2%)Coulouarn et al.2008COULOUARN_LIVER_CANCER_TGF_BETA_LATE_VS_EARLY_UP, \_DNTGFB_Coulouarn249215 (86.3%)110 (45.5%)244 (98.0%)42 (53.8%)Sakai et al.2008SAKAI_TUMOR_INFILTRATING_MONOCYTES_UP,\_DNMonocyte_Sakai108104 (96.3%)51 (21.1%)106 (98.1%)23 (29.5%)Woo et al.2008WOO_LIVER_CANCER_RECURRENCE_UP,\_DNRecurrence_Woo185185 (100.0%)176 (72.7%)185 (100.0%)61 (78.2%)Yamashita et al.2008YAMASHITA_LIVER_CANCER_STEM_CELL_UP,\_DNCSC_Yamashita112104 (92.9%)143 (59.1%)112 (100.0%)42 (53.8%)Yamashita et al.2008YAMASHITA_LIVER_CANCER_WITH_EPCAM_UP,\_DNEPCAM_Yamashita7065 (92.9%)135 (55.8%)68 (97.1%)32 (41.0%)Hoshida et al.2009HOSHIDA_LIVER_CANCER_SUBCLASS_S3,\_S1S1_Hoshida498492 (98.8%)170 (70.2%)498 (100.0%)60 (76.9%)Hoshida et al.2009HOSHIDA_LIVER_CANCER_SUBCLASS_S3,\_S2S2_Hoshida379370 (97.6%)179 (74.0%)379 (100.0%)53 (67.9%)Yoshioka et al.2009YOSHIOKA_LIVER_CANCER_EARLY_RECURRENCE_UP,\_DNRecurrence_Yoshioka10580 (76.2%)NA100 (95.2%)NAAndersen et al.2010ANDERSEN_LIVER_CANCER_KRT19_UP, \_DNCK19_Andersen11096 (87.3%)177 (73.1%)109 (99.1%)60 (76.9%)Roessler et al.2010ROESSLER_LIVER_CANCER_METASTASIS_UP,\_DNMetastasis_Roessler161148 (91.9%)NA155 (96.3%)NAWoo et al.2010WOO_LIVER_CANCER_CHOLANGIOCA_LIKE_UP, \_DNCC_Woo625599 (95.8%)205 (84.7%)616 (98.6%)67 (85.9%)Minguez et al.2011MINGUIZ_LIVER_CANCER_VASCULAR_INVASION_UP, \_DNVI_Minguez3533 (94.3%)109 (45.0%)34 (97.1%)31 (39.7%)Chew et al.2012Lymphocyte_infiltration_signature[c](#tf0015){ref-type="table-fn"}Lymphocyte_Chew1414 (100.0%)NA13 (92.9%)24 (30.8%)Kim et al.2012Overall_survival_signature[c](#tf0015){ref-type="table-fn"}OS_Kim6565 (100.0%)174 (71.9%)65 (100.0%)59 (75.6%)Roessler et al.2012Poor_outcome_signature[c](#tf0015){ref-type="table-fn"}G2_Roessler109 (90.0%)35 (14.5%)10 (100.0%)NALim et al.2013Disease_free_survival_signature[c](#tf0015){ref-type="table-fn"}DFS_Lim3018 (60.0%)NA26 (86.7%)NAKo et al.2014VDAC1_signature[c](#tf0015){ref-type="table-fn"}VAG_Ko4545 (100.0%)74 (30.6%)45 (100.0%)19 (24.4%)[^2][^3][^4]

2.2. Identification of Gene Expression Datasets and Data Processing {#s0020}
-------------------------------------------------------------------

The NCBI GEO ([http://www.ncbi.nlm.nih.gov/geo/](http://www.ncbi.nlm.nih.gov/geo){#ir0120}) and ArrayExpress ([http://www.ebi.ac.uk/arrayexpress/](http://www.ebi.ac.uk/arrayexpress){#ir0125}) databases were searched to identify datasets that had determined the prognostic effects of genome-wide gene expression levels. Eligible datasets should have determined the gene expression level in the HCC tumor tissues at the genome-wide level and provided the OS time and the corresponding status (alive or dead) at the last follow-up. OS was defined as the time range from the day of surgery to death or the last follow-up. Datasets that only provided gene expression levels in adjacent normal tissues or did not provide prognostic information for the patients were excluded. Initially, 97 datasets were identified for HCC, and 78 were excluded because they were based on formalin-fixed, paraffin-embedded (FFPE) tissues, cell lines, non-tumor tissues, or animal models. Additionally, 17 datasets that did not provide prognostic information for the HCC patients were also excluded after we carefully checked the original reports or emailed the authors. GEO: [GSE14520](ncbi-geo:GSE14520){#ir0130} ([@bb0255], [@bb0260]) and GEO: [GSE54236](ncbi-geo:GSE54236){#ir0135} ([@bb0310]) datasets fully met the inclusion criteria and were defined as the validation case-cohorts for the gene signatures in our current study.

[GSE14520](ncbi-geo:GSE14520){#ir0140} dataset consisted of tissues from 242 patients with primary HCCs, who underwent radical resections between 2002 and 2003 at the Liver Cancer Institute and Zhongshan Hospital (Fudan University, Shanghai, China). From this cohort, 220 samples were analyzed with the Affymetrix HT Human Genome U133A Array ([GPL3921](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL3921){#ir0145} platform with 22,277 probes), and 22 samples were analyzed with the Affymetrix Human Genome U133A 2.0 Array ([GPL571](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GPL571){#ir0150} platform with 22,277 probes). The raw expression data were processed and normalized by the Robust Multi-Array Average (RMA) method and global median centering. The array series was combined according to the probe IDs, and batch effects were adjusted with empirical Bayes methods in the Combat package of R software. For genes with more than one probe set, the mean level was calculated to obtain the individual gene expression level. Detailed clinical information was provided by Roessler et al. ([@bb0255]).

[GSE54236](ncbi-geo:GSE54236){#ir0155} dataset consisted of tissues from 78 primary HCC patients who received surgery at the Modena Gastroenterology Unit, Italy ([@bb0310]). The gene expression levels of the HCC tissues were determined with the Agilent Whole Human Genome Microarray 4 × 44K array with 41,000 probes. The expression levels were processed with Agilent Feature Extraction Software, and the quantile normalized log2 signal intensity data were downloaded from the GEO datasets. The mean level for probes from the same gene was calculated to determine the gene expression level. Detailed information for the patients was provided by Villa et al. ([@bb0310]).

2.3. Recruitment of HCC Patients {#s0025}
--------------------------------

A retrospective study was performed for HCC patients (N = 60) who received surgery treatment with curative intent from July 2012 to February 2014 at the Eastern Hepatobiliary Surgery Hospital of the Second Military Medical University. Patients were included if they received curative resection surgery for the first time without any previous anticancer treatment including chemotherapy or radiotherapy. Patients were excluded if they received palliative treatments, had a distant metastasis, had a history of other malignancies, received a liver transplant or were unwilling to participate in the study. All patients were diagnosed with HCC based on the pathological examination. Personal characteristics and clinicopathological characteristics of the patients were extracted from the medical records and assessed by the clinicians. The results of the preoperative biochemical tests and image evaluations were also retrieved. The resection treatments and surgical procedures were performed following the general guidelines that had been designed according to tumor size, location, and liver functional reserve ([@bb0325]). Patient follow-up was performed by telephone calls or checking the medical records at half-year intervals, and the last follow-up was performed in September 2016.

An independent validation case cohort was recruited from November 2009 to March 2010 in the same hospital (N = 78). The inclusion and exclusion criteria were similar to the previous case cohort. The last follow-up was performed September 2012 with the longest follow-up period extending up to 39 months. Detailed participant information is provided as Supplementary Table 3. Each participant provided written consent, and the institutional review board of the Second Military Medical University approved the study.

2.4. Immunohistochemical (IHC) Staining Methods {#s0030}
-----------------------------------------------

For the HCC patients, FFPE tumor tissues were used by the National Engineering Center for Biochip, Shanghai, to construct tissue microarrays (TMAs). For each patient, a 0.75-mm diameter core of the cancer FFPE tissue was punched and arranged in the TMA blocks. Sections of the TMAs (6-μm thick) were used to determine the expression levels of RAD21, CDK1, and HDAC2 following general IHC staining protocols. In brief, the TMAs were deparaffinized with xylene and rehydrated with graded ethanol solutions. To quench endogenous peroxidase activity, the TMA was treated with 3% hydrogen peroxide for 15 min at room temperature. Then, the sections were put into citric acid solution (pH = 6.0) and boiled at 95 °C for 40 min. After cooling, the sections were washed three times with phosphate-buffered saline (PBS) and blocked in 5% fetal bovine serum for 15 min at room temperature. Primary antibodies for CDK1 (1:150; Abcam, USA), HDAC2 (1:200; Abcam), and RAD21 (1:50; Santa Cruz, USA) were added to the sections, which were incubated at 4 °C overnight. After washing three times with PBS, the sections were incubated with a peroxidase-polymer labeled rabbit anti-mouse secondary antibody, followed with diaminobenzidine staining to detect peroxidase activity. Finally, the sections were counterstained with hematoxylin and differentiated in hydrochloric acid alcohol, followed by dehydration and mounting.

Expression was assessed by the staining intensity and the distribution of the positive cells. Intensity was categorized as 0--3 (0, negative; 1, weak; 2, moderate; 3, strong), and the distribution of positive cells was grouped as 1, 0--25%; 2, 25--50%; 3, 50--75%; and 4, \> 75%. The immunoreactive score (IRS) was calculated by multiplying the intensity with the distribution of positive cells ([@bb0335]), and the median IRS score was applied to categorize the HCC patients into high and low protein expression levels.

2.5. Construction of the PPI Network {#s0035}
------------------------------------

For those gene signatures significantly that were associated with the prognosis of the HCC patients in both case cohorts, PPI networks for these genes were constructed with the Reactome FI plugin of the Cytoscape software (Version 3.2.0; <http://www.cytoscape.org/>) ([@bb0275], [@bb0370]). With the Network Analyzer plugin (Version 1.0; <http://med.bioinf.mpi-inf.mpg.de/netanalyzer/>) ([@bb0010]), the basic topological parameters, including the degree of node distribution, the shortest path length distribution, and the average clustering coefficient distribution were assessed.

2.6. Cell Culture and siRNA Transfection Methods {#s0040}
------------------------------------------------

The human liver cancer cell lines Hep3B, SMMC-771 and Huh-7 were purchased from the Cell Bank of Chinese Academy of Sciences (Shanghai, China). The CSQT-2 cell line, which was derived from the portal vein tumor thrombi (PVTT) of an HCC patient and established by Dr. Cheng\'s lab ([@bb0345]), was kindly provided by Dr. Cheng\'s lab. All cell lines were cultured in Dulbecco\'s modified Eagle medium supplemented with 10% fetal bovine serum, 100 μg/mL of streptomycin, 4.5 mg/mL of [d]{.smallcaps}-glucose, 300 mg/L of [l]{.smallcaps}-glutamine, and 110 mg/L of sodium pyruvate. The cell lines were maintained in an incubator with a humidified atmosphere of 5% CO~2~ at 37 °C.

In the siRNA transfection assays, 5 × 10^5^ cells/well were plated in 6-well cell culture plates. The siRNA duplexes for CDK1, RAD21, and HDAC2 or the scramble control were synthesized by GenePharma (Shanghai, China) and were transfected with Lipofectamine 2000 reagent (Life Technologies, USA) at a concentration of 40 nmol/L following the manufacturer\'s guidelines. After 48 h, the endogenous protein levels in the transfected cells were determined by Western blotting.

2.7. Determination of Cell Viability and Proliferation {#s0045}
------------------------------------------------------

Cells (2000 cells/well) were plated in 96-well plates, and 24 h later, the siRNA duplexes for CDK1, RAD21, and HDAC2 or the scramble control were transfected into CSQT-2 cells (40 nmol/L). 24, 48 and 72 h after transfection, the CCK-8 solution was added to the cells, and the preparations were incubated for another 4 h before the absorption values (450 nm) were determined.

To determine the anti-cancer activities of the CDK1 selective inhibitor RO-3306 (Selleck, China), liver cancer cells (3000 per well) were plated in 96-well plates. After 24 h, RO-3306 was added to the cells at concentrations of 0 (vehicle, DMSO), 0.78, 1.56, 3.13, 6.25, 12.5, or 25 μM. The cells were cultured for another 48 h, and CCK-8 solution was applied to determine the cellular viability following the manufacturer\'s guidelines. To determine the anti-proliferation activity of RO-3306, liver cancer cells (3000 per well) were plated in 96-well plates, and the vehicle (DMSO) or RO-3306 (12.5 μM) was added; after 24, 48, or 72 h, CCK-8 was applied to determine the cellular proliferation.

2.8. Western Blotting Methods {#s0050}
-----------------------------

Cells were lysed with radio-immunoprecipitation assay (RIPA) buffer containing a cocktail of protease inhibitors (Sigma, USA). Protein concentrations were measured by the bicinchoninic acid assay (Sigma, USA), and total protein (30 μg) was separated on 10% SDS-PAGE gels and transferred onto polyvinylidene fluoride (PVDF) membranes (Millipore, USA). Membranes were blocked with 5% skim milk for 1 h and then probed overnight at 4 °C with the same antibodies as in the IHC staining tests. After washing 3 times, the PVDF membranes were incubated with secondary horseradish peroxidase-linked secondary antibody for 1 h at room temperature. The signaling intensity was determined with an enhanced chemiluminescence detection reagent and visualized with X-ray films.

2.9. Statistical Analyses {#s0055}
-------------------------

To determine the prognostic effects of the gene signatures, the nearest template prediction (NTP) method implemented in the Gene Pattern software (Broad Institute of Harvard and MIT, Boston, MA) was used to make class prediction of the HCC patients based on the gene-expression data and the list of signature genes ([@bb0100]). Templates of the "poor prognosis" and "good prognosis" patterns for each gene signature were defined as those genes associated with worse or better outcomes, respectively. Subjects closer to "poor" or "good" prognosis templates with a false discovery rate (FDR) \< 0.05 were classified as poor or good outcome, respectively. Those with the FDR \> 0.05 were recognized as an unclassified group. Cramer\'s V test was calculated to test the concordance rate of the prediction class for the patients by the gene signatures ([@bb0075]). Values \< 0.40 indicated a weak correlation between the gene signatures, values between 0.40 and 0.60 indicated substantial correlation, and values \> 0.60 indicated strong correlation. Kaplan-Meier plots, together with the log-rank tests, were applied to identify gene signatures that were associated with the OS of the patients. Univariate Cox regressions were applied to determine the associations between the basic characteristics or the gene signatures and OS of the patients. Due to the collinearity for the variables of the characteristics and the NTP prediction outcomes, the associations between the variables and OS of patients were assessed with the random survival forest method, which was developed for right-censored data ([@bb0125]). Variable predictiveness was assessed with the variable importance (VIMP) measures for individual factors in the random survival forests model ([@bb0125]). A positive VIMP value indicated that the misspecification detracted from the predictive accuracy in the forest for the variables and that the predictive power of the forest depended on these variables. Zero or negative VIMP values suggested that the variables contributed nothing to predictive accuracy or even contributed noise to the prediction models and that these variables should be filtered out from the models. In the random survival forest, 5000 trees were grown using a log-rank, score-splitting algorithm. For evaluations, the VIMP for each variable was recorded. The analysis was independently repeated 100 times, and the VIMP was averaged for each variable.

For the TMA cohorts from the Eastern Hepatobiliary Surgery Hospital, univariate Cox regressions were performed to evaluate the basic characteristics and the IHC scores of the biomarkers that were associated with OS. Backward stepwise multivariate Cox regression analyses were performed to identify the independent factors that contribute to the OS of HCC patients. Only significant factors in the univariate analyses were introduced into the multivariate Cox model.

Differences in demographic characteristics and selected variables were evaluated with the χ^2^ test (for categorical variables) or Student\'s *t*-test (for continuous variables). Comparisons between the multiple groups were performed using one-way ANOVA to determine the overall significance. The data are presented as the means ± SEM, unless otherwise indicated. All analyses were performed with R software (Version 3.3.1; [www.r-project.org](http://www.r-project.org){#ir0170}) and related packages, and P \< 0.05 for two-sided tests was recognized as statistically significant.

3. Results {#s0060}
==========

3.1. The Nearest Template Prediction Results for HCC Patients {#s0065}
-------------------------------------------------------------

A total of 30 gene signatures were identified that might be associated with the prognosis for HCC patients ([Table 1](#t0005){ref-type="table"}). The number of genes ranged from 10 to 625, and 60% to 100% of these genes were covered by platforms [GSE14520](ncbi-geo:GSE14520){#ir0175} and [GSE54236](ncbi-geo:GSE54236){#ir0180} ([Table 1](#t0005){ref-type="table"}). For each dataset, 23 of the 30 gene signatures successfully classified the HCC patients into poor or good outcomes (FDR P \< 0.05). The number of patients enriched with the gene signature ranged from 35 (14.5%) to 205 (84.7%) in [GSE14520](ncbi-geo:GSE14520){#ir0185} and from 19 (24.4%) to 69 (88.5%) in [GSE54236](ncbi-geo:GSE54236){#ir0190} ([Table 1](#t0005){ref-type="table"}). The NTP prediction results are provided in [Fig. 1](#f0005){ref-type="fig"}. Cramer\'s V test suggested that there were three major groups for the prediction results of the gene signatures in the two cohorts ([Fig. 1](#f0005){ref-type="fig"}b and d). The first class contained mainly gene signatures that indicated the progenitor tumor cell origin (CSC_Yamashita ([@bb0390]), EPCAM_Yamashita ([@bb0390]), CK19_Andersen ([@bb0005]), S2_Hoshida ([@bb0105]) and C2_Cario ([@bb0030])); cellular proliferation (Proli_Chiang ([@bb0045])); and vascular invasion (VI_Minguez ([@bb0205])). The second class contained those gene signatures of TGF-beta_Coulouarn ([@bb0050]), MET_Kaposi-Novak ([@bb0135]), G3_Boyault ([@bb0020]), S1_Hoshida (TGFβ-WNT) ([@bb0105]), Recurrence_Woo ([@bb0365]), and OS_Kim ([@bb0140]). The third class contained the gene signatures of CTTNB1_Chiang ([@bb0045]), Interferon_Chiang ([@bb0045]), G6_Boyault (CTTNB1_WNT activation) ([@bb0020]), and G5/6_Boyault (CTTNB1_WNT activation) ([@bb0020]).Fig. 1Nearest template prediction (NTP) results and their concordance with gene signatures in the [GSE14520](ncbi-geo:GSE14520){#ir0005} and [GSE54236](ncbi-geo:GSE54236){#ir0010} datasets. (a) NTP results in dataset [GSE14520](ncbi-geo:GSE14520){#ir0015} (N = 242), with each column representing the prediction results for individual patients. Gene signatures suggesting poorer overall survival (OS) are labeled in blue, and signatures that suggest better OS are labeled in yellow (FDR, P \< 0.05). The gray column indicates the presence of an unclassified group of patients (FDR, P \> 0.05). The left label indicates the gene signature name, as listed in [Table 1](#t0005){ref-type="table"}. (b) Heat map of Cramer\'s V coefficient values for pair-wise gene signatures in [GSE14520](ncbi-geo:GSE14520){#ir0020}; the signatures are clustered according to their degree of correlation. (c) NTP results in dataset [GSE54236](ncbi-geo:GSE54236){#ir0025} (N = 78), with each column representing the prediction result for individual patients. Poorer (FDR, P \< 0.05), better (FDR, P \< 0.05), or unclassified (FDR \> 0.05) outcomes for each patient are labeled in blue, yellow, or gray, respectively. The left label indicates the gene signature name as listed in [Table 1](#t0005){ref-type="table"}. (d) Heat map of Cramer\'s V coefficient values for pair-wise gene signatures in [GSE54236](ncbi-geo:GSE54236){#ir0030}; the signatures are clustered according to their degree of correlation. Gene signatures that are significantly associated with the OS of HCC patients are labeled in red, and those not associated with OS are labeled in blue.Fig. 1

3.2. Association of Gene Signatures With the OS of HCC Patients {#s0070}
---------------------------------------------------------------

In dataset [GSE14520](ncbi-geo:GSE14520){#ir0195}, the univariate Cox analyses showed that tumor size, nodular number (multiple vs. single), cirrhosis, AFP level, BCLC stage, CLIP stage and TNM stage were associated with the OS of the patients (Table S1). Of the 23 gene signatures in [GSE14520](ncbi-geo:GSE14520){#ir0200}, 15 were associated with the OS of the HCC patients, as indicated by Kaplan-Meier plots and log-rank tests ([Fig. 1](#f0005){ref-type="fig"}, [Fig. 2](#f0010){ref-type="fig"}). For [GSE54236](ncbi-geo:GSE54236){#ir0205}, the univariate Cox analyses indicated that the doubling time for HCC was associated with the OS of HCC patients (Table S1). Kaplan-Meier plots showed that, in dataset [GSE54236](ncbi-geo:GSE54236){#ir0210}, 12 gene signatures were associated with the OS of the HCC patients ([Fig. 1](#f0005){ref-type="fig"}, [Fig. 3](#f0015){ref-type="fig"}). Univariate Cox analyses for the gene signatures that categorized HCC groups (poor or unclassified vs. good) are provided as Table S2. Eight and 11 gene signatures were not associated with the OS of HCC patients in [GSE14520](ncbi-geo:GSE14520){#ir0215} (Fig. S1) and [GSE54236](ncbi-geo:GSE54236){#ir0220} (Fig. S2), respectively. Overall, 11 gene signatures were associated with the OS for HCC patients in both case cohorts (Table S3).Fig. 2Kaplan-Meier plots and log-rank tests for the 15 gene signatures that are associated with the overall survival of HCC patients in [GSE14520](ncbi-geo:GSE14520){#ir0035}.Fig. 2Fig. 3Kaplan-Meier plots and log-rank tests for the 12 gene signatures that are associated with the overall survival of HCC patients in [GSE54236](ncbi-geo:GSE54236){#ir0040}.Fig. 3

To test the prognostic performance of the gene signatures, a random survival forest algorithm was applied to determine the VIMP values of the basic characteristics and the gene signatures ([Fig. 4](#f0020){ref-type="fig"}). In [GSE14520](ncbi-geo:GSE14520){#ir0225}, the top-ranked variables after 100 runs were BCLC stage; TNM stage; CLIP stage; cirrhosis status; and gene signatures including Recurrence_Wang ([@bb0340]), OS_Lee ([@bb0165]), CK19_Andersen ([@bb0005]), Monocyte_Sakai ([@bb0265]), CC_Woo ([@bb0360]), MET_Kaposi-Novak ([@bb0135]), and EPCAM_Yamashita ([@bb0390]). For [GSE54236](ncbi-geo:GSE54236){#ir0230}, the variables in the random survival forests with positive VIMP values were MET_Kaposi-Novak ([@bb0135]), G3_Boyault ([@bb0020]), Proli_Chiang ([@bb0045]), doubling time, CSC_Yamashita ([@bb0390]), CK19_Andersen ([@bb0005]), CC_Woo ([@bb0360]), and TGF-β_Coulouarn ([@bb0050]). These results suggest that gene signatures have higher predictive values than conventional factors in predicting of the OS of HCC patient.Fig. 4Random survival forests and the corresponding VIMP values for gene signatures in prediction of overall survival for HCC patients in datasets [GSE14520](ncbi-geo:GSE14520){#ir0045} (N = 242) and [GSE54236](ncbi-geo:GSE54236){#ir0050} (N = 78). The error rates according to the number of trees generated in the random survival forest analyses in [GSE14520](ncbi-geo:GSE14520){#ir0055} (a) and [GSE54236](ncbi-geo:GSE54236){#ir0060} and (c). The mean VIMP values for each variable after 100 runs are provided in [GSE14520](ncbi-geo:GSE14520){#ir0065} (b) and [GSE54236](ncbi-geo:GSE54236){#ir0070} (d).Fig. 4

3.3. Construction of the Functional PPI Network {#s0075}
-----------------------------------------------

For the 11 gene signatures that were significantly associated with the OS of HCC patients, 1626 individual genes were covered. With the ReactomeFI plugin in the Cytoscape, a PPI network was constructed with 1406 nodes and 10,135 edges (Fig. S3a). The topological analysis of the PPI network suggested that these 11 gene signatures constituted a scale-free biological signaling network (Fig. S3b-3c). The top-ranked non-linker nodes included EP300, RPS27A, CDK1, RAD21, RPS27, HDAC2, and CTNNB1; the top-ranked linker nodes were UBC, MYC, JUN, SP1, PLK1, EED, ACTB, RXRA, and STAT3 (degree \> 90). A simplified PPI network with those genes of node degree \> 60 is provided in [Fig. 5](#f0025){ref-type="fig"}. We hypothesized that the core genes in the networks may have prognostic predictive values for HCC patients. Because transcription coactivator EP300 and ribosomal proteins RPS27A and RPS27 are not ideal biomarkers or therapeutic targets for HCC, CDK1, RAD21, and HDAC2 were chosen for subsequent analysis because they had relatively high degrees in the PPI network.Fig. 5The core functional PPI network derived from the 11 gene signatures that were significantly associated with the overall survival of HCC patients (genes with node degree \> 60). The red nodes are genes included in the gene signature, and degree nodes are linker genes in the network construction derived from the Reactome FI plugin of Cytoscape. The size of the node correlates with the degree of the indicated gene in the network. CDK1, HDAC2, RAD21, EP300, RPS27A and RPS27 were genes with the top-ranked degrees.Fig. 5

3.4. Expression Patterns of Potential Prognostic Biomarkers in HCC Tissues {#s0080}
--------------------------------------------------------------------------

We constructed TMAs for HCC patients to determine the prognostic values of the core genes with the IHC staining method (N = 60). Detailed patient clinical information is provided in Table S3. We found that the expression levels of CDK1, HDAC2 and RAD21 were increased in tumor tissues compared with the adjacent normal tissues ([Fig. 6](#f0030){ref-type="fig"}a). CDK1 was expressed in the cytoplasm of the cancer cells, but no expression was evident in normal tissues (Fig. S4; Wilcoxon test, P \< 0.001). Higher expression of CDK1 was associated with worse outcomes for HCC patients (log-rank test, P = 0.001; [Fig. 6](#f0030){ref-type="fig"}b). HDAC2 was expressed in the cytoplasm of tumor cells and was overexpressed in HCC tissues (Fig. S4; Wilcoxon test, P \< 0.001). Higher expression correlated with poorer OS of HCC patients (log-rank test, P = 0.001; [Fig. 6](#f0030){ref-type="fig"}b). RAD21 was immunoreactive mainly in the nuclei of HCC cells (Fig. S4); only weak nuclear staining of RAD21 was evident in normal liver cells (Wilcoxon test, P \< 0.001). Higher nuclear staining of RAD21 in HCC cells correlated with worse OS of HCC patients (log-rank test, P = 0.026; [Fig. 6](#f0030){ref-type="fig"}b). The univariate analyses of the clinical characteristics and the IHC scores of CDK1, HDAC2, and RAD21 are provided in [Table 2](#t0010){ref-type="table"}. Multivariate Cox analyses showed that CDK1 level, tumor size, and satellite nodule status were independent prognostic factors for the OS of HCC patients ([Table 2](#t0010){ref-type="table"}).Fig. 6The protein expression levels of RAD21, CDK1, and HDAC2 in tumor and adjacent normal HCC tissues and their associations with overall survival (OS) for HCC patients. (a)CDK1, HDAC2, and RAD21 were significantly increased in HCC tissues compared with adjacent normal tissues (Wilcoxon signed rank test, P \< 0.001). (b) Higher expression levels of CDK1 (log-rank test, P = 0.001), HDAC2 (log-rank test, P = 0.014), and RAD21 (log-rank test, P = 0.027) in the HCC tissues were associated with worse OS of the patients compared with lower expression levels.Fig. 6Table 2Univariate and multivariate analysis of the clinical and pathological characteristics for the overall survival of HCC patients (N = 60).Table 2CharacteristicsUnivariate analysisMultivariate analysisHR (95% CI)P-valueHR (95% CI)P-valueAge, per year0.98 (0.94--1.02)0.258Sex (Male vs. Female)0.77 (0.29--2.04)0.599HbeAg (Positive vs. Negative)0.84 (0.32--2.23)0.727Tumor diameter (\> 3 vs. ≤ 3 cm)3.73 (1.12--12.45)0.0333.62 (1.02--12.79)0.046Multiple nodules (Yes. vs. No)5.06 (2.14--7.79)\< 0.0015.48 (2.09--14.37)\< 0.001Tumor encapsulation Complete vs. Absence0.58 (0.23--1.47)0.25 Incomplete vs. Absence0.53 (0.20--1.38)0.192Cirrhosis (Child-Pugh B + C vs. A)1.25 (0.57--2.74)0.571Tumor differentiation (III vs. II)2.98 (0.70--12.64)0.138Microscopic vascular invasion (Yes vs. No)3.27 (1.47--7.24)0.0042.12 (0.94--4.75)0.069BCLC stage (B + C vs. 0 + A)4.56 (2.09--9.93)\< 0.001AFP (\> 20 vs. ≤ 20 ng/mL)2.93 (1.01--8.53)0.048γ-GT (\> 50 vs. ≤ 50 U/L)2.87 (0.99--8.35)0.053RAD21 (High vs. Low)2.49 (1.08--5.76)0.033HDAC2 (High vs. Low)3.21 (1.21--8.53)0.019CDK1 (High vs. Low)3.93 (1.65--9.39)0.0024.05 (1.63--10.03)0.003[^5]

We further validated the prognostic values of CDK1 in an independent case cohort (N = 78; Table S3). HCC patients with higher CDK1levels were associated with poor OS compared with those have lower CDK1 level, as suggested by the log-rank test (P = 0.006; Fig. S5). The multivariate Cox analyses also suggested that CDK1 was also an independent risk factor for HCC patients in the validation cohort (Table S4).

3.5. CDK1 is a Potential Therapeutic Target for HCC {#s0085}
---------------------------------------------------

The specificity of the antibodies for the IHC staining and the roles of these proteins in HCC progression were confirmed with siRNA methods in cell models. Knockdown of CDK1, RAD21, and HDAC2 with siRNAs led to reduced proliferation of CSQT-2 cells (Fig. S6a). Knockdown of RAD21 reduced the levels of CDK1, but not HDAC2. Knockdown of HDAC2 did not affect the protein expression of CDK1 or RAD21 (Fig. S6b). These results indicate that RAD21 might regulate the CDK1 activity in HCC tumor cells.

Because CDK1 was an independent prognostic factor for HCC, we determined whether CDK1 could be a therapeutic target for HCC. An inhibitor (RO-3306) of CDK1 significantly reduced cellular viability (Supplementary [Fig. 6](#f0030){ref-type="fig"}c) and proliferation (Supplementary [Fig. 6](#f0030){ref-type="fig"}d) for HCC cell lines, including Hep3B, SMMC-7721, Huh-7 and CSQT-2, suggesting that CDK1 could be a target for HCC treatment.

4. Discussion {#s0090}
=============

An analysis of the biological features of HCC is necessary for personalized therapy. Various studies have reported molecular classifications and prognostic molecular signatures for HCC based on the gene expression from HCC tissues or adjacent non-tumoral tissues, which have revealed the tumor heterogeneity \[15-42\]. With the NTP methods, we determined the prognostic effects of the reported gene signatures in tumor tissues and found that the predictive roles of these gene signatures were reproducible between the datasets. With the random forest survival method, we compared the VIMP values for gene signatures and clinical factors and found that the gene signatures were superior to the clinical characteristics of patients, such as tumor size, nodular status, and the cirrhosis status, for [GSE14520](ncbi-geo:GSE14520){#ir0235} and the doubling time for [GSE54236](ncbi-geo:GSE54236){#ir0240}, indicating the values of gene signatures in the prognostic prediction of HCC patients. Interestingly, the gene signatures that were associated with the OS of the patients were in high concordance, and the genes from the signatures were functionally linked with each other. These results suggest that the predictive abilities for the gene signatures are reproducible and that they might contribute to personalized prognosis prediction for HCC patients.

Based on 287 HCC patients, Villanueva et al. determined the predictive effects of early recurrence for 18 gene signatures derived from HCC tissues and 4 from adjacent non-tumor tissues ([@bb0320]). The genomic gene expression profiling was determined for FFPE tumor specimens and adjacent tissues, and the NTP method was applied to identify those patients with a tendency for early recurrence. They found that only the G3_Boyault gene signature ([@bb0020]), derived from HCC tissues, and another gene signature generated in adjacent non-tumor cirrhotic tissues ([@bb0110]) were significantly associated with early recurrence or overall recurrence for HCC patients. However, the other 17 tumor-derived gene signatures were not associated with recurrence. Our current study examined the associations between the prediction results of the gene signatures and the recurrence of HCC patients in [GSE14520](ncbi-geo:GSE14520){#ir0245} and found that only gene signature OS_Kim ([@bb0140]) was associated with recurrence (data not shown). However, we demonstrated that ten of these gene signatures were predictors for the OS of HCC patients in two independent case cohorts, [GSE14520](ncbi-geo:GSE14520){#ir0250} and [GSE54236](ncbi-geo:GSE54236){#ir0255}. These results indicate that, these gene signatures have promising predictive effects for the OS of HCC patients but not for the risk of recurrence. Although disease recurrence is a prognostic factor for the death of HCC patients, other clinical factors and treatment methods also contribute to survival. In future studies, gene signatures that confer the recurrence risk and gene signatures derived from the tumor microenvironment that are associated with the prognosis for HCC patients need to be identified.

Although there were few overlapping genes among the 11 gene signatures (data not shown), they formed a tightly linked, scale-free biological PPI network, as suggested by the node degree distribution following a power algorithm ([@bb0015]). We hypothesized that the core genes with high degrees in the network might have important biological functions in the signaling transduction and that their expression levels might have prognostic values. With the in-house HCC tissue samples, the prognostic values for these genes were determined. The expression levels of the core genes RAD21, HDAC2, and CDK1 were increased in HCC tissues compared with adjacent non-tumor tissue, and their expression levels were associated with the OS of HCC patients. As determined with multiple Cox analyses, CDK1, but not RAD21 or HDAC2, when adjusted for clinical characteristics, was an independent prognostic factor for HCC patients.

For various cancer types, HDAC2 acts as an oncogene through the epigenetic regulation of genes and the corresponding signaling cascades in cancer development, and HDAC2 expression is gradually increases, from pre-neoplastic lesions, to low-grade dysplastic nodules, high-grade dysplastic nodules, and HCCs ([@bb0210]). Higher HDAC2 levels are correlated with poor survival of HCC patients ([@bb0175], [@bb0250]), which is consistent with results of the current study. In HCC cells, inhibiting of HDAC2 disrupts the G1/S phase of the cell cycle and leads to apoptosis through upregulating the total p21, p27, and acetylated p53 levels and reducing CDK6 and BCL2 levels ([@bb0170], [@bb0220]); these results suggest that HDAC2 could be a therapeutic target for HCC. In a murine xenograft model, systemic delivery of HDAC2 siRNA encapsulated in lipid nanoparticles reduced the growth of human HCC ([@bb0170]); however, this method is far from clinical use. Two small molecule inhibitors of HDACs (HDACis), SAHA (vorinostat) and FK-228 (romidepsin), have been approved by the U.S. Food and Drug Administration (FDA) to treat refractory cutaneous and peripheral T cell lymphoma ([@bb0355]). In addition to these agents, \> 20 different HDACis have produced encouraging results for the treatment of hematological malignancies, including Hodgkin\'s lymphoma, multiple myeloma, and acute myelocytic leukemia; however, the therapeutic effects of HDACis on solid tumors have been disappointing ([@bb0355]). In addition to toxicity, the off-target actions of the HDACis may lead to treatment failure for solid tumors. Thus, inhibitors that are selective for HDAC2 should be developed, and their therapeutic effects in HCC patients need to be addressed.

RAD21, a component of the cohesion complex, is essential for chromosome segregation during the metaphase-anaphase transition of mitosis ([@bb0380]). RAD21 is also involved in homologous recombinational repair or the error-free repair of DNA damage, which could influence the sensitivity of gastrointestinal and breast cancers to radiotherapy or chemotherapy ([@bb0375], [@bb0385]). High levels of nuclear RAD21 staining correlate with poor disease-specific survival of colorectal cancer patients with KRAS mutations ([@bb0055]) and with early relapse in patients with high-grade luminal, basal, or HER2 breast cancers ([@bb0385]). However, the roles of RAD21 in HCC development and progression have not been determined. In the current study, we found that nuclear RAD21 was increased in HCC tissues compared with adjacent non-tumor tissues, and higher RAD21 levels were associated with shorter OS of HCC patients. In HCC cells, RAD21 knockdown reduced cellular proliferation and down-regulated CDK1 levels, which might partially underlie the RAD21 oncogenic activities in HCCs. These results suggest that RAD21 could be a biomarker or therapeutic target for HCC patients and that the potential intervention methods need to be developed.

CDK1 is a cyclin-dependent kinase that plays critical roles in the regulating of cellular mitosis. Depending on its association with cyclin A or B, it participates in the progression of the G1/S and G2/M phases of the cell cycle through the phosphorylation of various substrates, including Ajuba ([@bb0035]), CDP/Cux ([@bb0270]), Bcl2 ([@bb0300]), and Wee1 ([@bb0090]) ([@bb0245]). Quantitative phosphoproteomics has identified \> 500 candidate substrates for CDK1; these substrates are associated with genes that are G2 and M phase-specific ([@bb0245]). In addition to its roles in mitosis, CDK1 also participates in the regulation of self-renewal, differentiation, and somatic reprogramming of human embryonic stem cells ([@bb0350]). CDK1 also stimulates the enzymatic activity of SIRT3, which enhances mitochondrial function and tumor radioresistance ([@bb0190]). Hyperactivation of CDK1 is associated with poor prognosis for patients with lung adenocarcinoma ([@bb0280]), ovarian cancer ([@bb0395]), renal cell carcinoma([@bb0095]), and breast cancer ([@bb0240]). For lymphomas, hepatoblastomas, and breast cancers, the inhibition of CDK1 downregulates survivin expression and induces MYC-dependent apoptosis ([@bb0085], [@bb0130]). In the current study, we found that CDK1 was detectable in HCC cells but not in normal liver tissues and that high CDK1 independently correlated with short OS. Considering its biological roles, CDK1 expression in HCC cells might reflect proliferation status and cancer stem cell properties, which are associated with the OS of HCC patients ([Fig. 1](#f0005){ref-type="fig"}b and d). As determined with cultured cells, CDK1 knockdown or inhibition correlated with reduced cellular proliferation, suggesting that CDK1 is a therapeutic target for HCC. Various inhibitors of CDK1, including flavopiridol, BMI-1026, olomoucine, staurosporine, and RO-3306 have been developed, and some have entered phase I and II clinical trials for the treatment of a variety of solid tumors and hematologic malignancies ([@bb0330]). For most of these inhibitors, however, their selective activity is poor; they generally inhibit CDK1, 2, 4, and 6 with equal potency ([@bb0330]). As shown in early clinical trials, these inhibitors often lead to high toxicity. Selective CDK1 inhibitors can exert more favorable therapeutic effects. For example, a selective CDK1 inhibitor, RO-3306, induces cell cycle arrest and apoptosis in cancer cells but has minimal effects on normal cells ([@bb0305]). In the current study, RO-3306 reduced the proliferation of cultured HCC cells. However, whether selective inhibitors for CDK1 could act as monotherapy agents or show synergistic effects with other chemotherapeutic agents needs to be addressed.

In conclusion, we evaluated the prognostic capacity of 30 gene signatures and found that 11 were significantly associated with the OS of HCC patients in two HCC cohorts. The genes from the 11 signatures consisted of a scale-free functional PPI network. The protein expression levels of the core nodes, RAD21, CDK1, and HDAC2, had prognostic value for HCC patients; however, only CDK1 was an independent prognostic factor. Further, because inhibition of CDK1 showed promising anticancer activity, it could serve as a therapeutic target for HCCs. In summary, the results provide potential biomarkers for the prediction of prognosis and present potential targets for the treatment of HCC patients. However, more studies are warranted to determine the roles of these proteins and to develop novel therapeutics for HCC.
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